RecruitingPhase 1Phase 2NCT07348055
A Study of GR1803 in Systemic Lupus Erythematosus
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Enrollment
44 participants
Start Date
Feb 2, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria4
- comfirmed diagnosis of systemic lupus erythematosus
- SLEDAI-2K≥6分
- written informed consent and ability to comply with protocol requirements
- have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Exclusion Criteria3
- with unstable acute and chronic diseases
- active infection
- history of malignant tumor within 5 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALGR1803 injection
step-up dosing, Dose and frequency according to the protocol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07348055
Related Trials
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
NCT071321121 location
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
NCT067927991 location
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
NCT067373801 location
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT068280421 location